CLERMONT-FERRAND, France, Dec. 2 /PRNewswire/ -- Quantel Medical, an
international market leader in ultrasound and laser systems for Ophthalmology
and Dermatology announced today that it has received the Food and Drug
Administrations (FDA) approval to market the non-ablative Aramis Er:Glass
1.54 nm Dermatology Laser for its use to treat acne on the back. Already
approved by the FDA for general dermatological use including dermal remodeling
and wrinkle reduction, the additional approval to market the Aramis laser for
the treatment of acne will provide patients with a new non-ablative treatment
option, with a shorter treatment cycle and no side effects as an alternative
to powerful drugs, antibiotics, topical creams and lotions.
Acne is a disease of the sebaceous gland of the skin and is caused by
clogged pores by the increased sebum production and the presence of bacteria.
This leads to a thickening or inflammation of the lining of the follicle,
resulting in less severe acne known as blackheads and whiteheads to
inflammatory papules and pustules, or to the most severe acne known as nodules
and cysts which can lead to scarring.
With more than 40% of teenagers and a significant percentage of the adult
population afflicted, acne is one of the most challenging conditions facing
physicians today. On average, American Dermatologists see 10-20 acne patients
per day. Other than Accutane and its numerous, often severe side effects that
include dry skin, birth defects and severe depression, a few of the options
available to physicians were to keep the infection under control, either using
oral and topical antibiotics, topical medication or blue light irradiation.
Oral antibiotics (erythromycin, minocyclin and tetracycline) may take several
months to clear up acne, can cause upset stomach, diarrhea, loss of appetite,
nausea, can reduce effectiveness of birth control and must be taken daily to
be effective or acne will return. Topical antibiotics are limited in their
ability to penetrate the skin and clear more deep seated acne and also need to
be taken for several months. Topical medication or creams are also limited in
their ability to penetrate the skin and cost Americans on average over
$100 million per year. Blue light therapy requires several treatments. In
all cases, only the symptoms were treated, not the cause. Using the Aramis, a
non-invasive laser is a huge discovery in the treatment of acne that's been a
long time coming for physicians needing a new treatment option.
Clinical studies both in Europe and the U.S. conclude that the Aramis
Laser treats the source of acne by altering the sebaceous gland. It reduces
sebum production and sterilizes the target, clearing acne and minimizing its
recurrence. Each individual treatment results in an approximate 25%
improvement with optimal results after just four treatments -- each at two-
week intervals. Patient satisfaction is high with no evidence of side
effects, edema, erythema and no pain. Patients also noticed an overall
improvement in the appearance of the skin.
Quantel Medical, the manufacturer of the Aramis Laser is an industry
leader worldwide. The company's luminaries have received International
Dermatological awards for their peer reviewed published clinical study papers.
The Aramis Laser is currently available in North America by Med-Surge
Technologies, exclusive distributor for Quantel Medical. In North America
please visit www.medsurgetech.com , or call 800-787-4417. In rest of world
please visit www.quantel-medical.fr , or call +33 (0)4 73 745 745.
Contacts: International North America
Christine Warren Beth Emmert
Quantel Medical Med-Surge Technologies
+33 (0)4 73 745 745 (972) 720-0425, ext. 223
SOURCE Quantel Medical